You must register to view and download the Settlement Notice and Settlement Proof.
December 5, 2013 - The court approved the settlement, entered the orders approving the plan of allocation, the motion for attorneys’ fees and expenses, and dismissed the action with prejudice.
July 25, 2013 - The court preliminarily approved the settlement.
May 24, 2013 - Parties filed a stipulation of settlement.
August 10, 2012 - The court granted in part and denied in part the defendants' motions to dismiss.
January 9, 2012 - The defendants filed motions to dismiss.
October 18, 2011 - The lead plaintiffs filed a third amended consolidated complaint.
August 25, 2011 - The court granted the defendants' motion to dismiss and granted lead plaintiffs leave to file an amended complaint.
October 13, 2010 - The defendants filed a motion to dismiss.
July 26, 2010 - The lead plaintiffs filed a second amended consolidated complaint.
May 10. 2010 - The lead plaintiffs filed an an amended consolidated complaint on behalf of investors who purchased Hansen Medical Inc (NASDAQ: HNSN) common shares between February 19, 2008 and October 18, 2009. The lead plaintiffs allege that the defendants violated the Securities Act of 1934 by issuing false and misleading statements between February 19, 2008 and October 18, 2009.
February 25, 2010 - The lead plaintiffs and lead counsel were appointed and all cases were consolidated.
December 22, 2009 - A lead plaintiff motion was filed.
November 13, 2009 - An additional investor filed a complaint.
November 4, 2009 - Another investor filed a complaint.
October 23, 2009 - An investor in shares of Hansen Medical Inc (NASDAQ: HNSN) has filed a lawsuit in the U.S. District Court for the Northern District of California against Hansen Medical Inc over alleged violations of Federal Securities Laws between May 1, 2008 and October 18, 2009.
According to the complaint the plaintiff alleges that Hansen Medical Inc and certain of its executive officers violated Federal Securities Laws by knowing or recklessly disregarding that their public statements concerning Hansen Medical Inc's business, operations and prospects were materially false and misleading. On October 19, 2009, Hansen Medical Inc announced that the audit committee of Hansen Medical Inc's board of directors, upon the recommendation of management, concluded thatHansen Medical Inc's previously issued financial statements contained in its annual report on Form 10-K for the year ended December 31, 2008, and Hansen Medical Inc's quarterly reports on Form 10-Q for the quarters ended March 31, 2008, June 30, 2008, September 30, 2008, March 31, 2009 and June 30, 2009, should no longer be relied upon because of errors arising from potential irregularities outside of the accounting department. In addition, Hansen Medical Inc indicated that the related press releases, reports and stockholder communications describing Hansen Medical Inc's financial statements for the identified periods and the report of Hansen Medical Inc's independent registered accounting firm, PricewaterhouseCoopers LLP,related to the year ended December 31, 2008 also should no longer be relied upon. According to the company, Hansen Medical Inc identified systems for which revenue should have been recognized in a later period than the period in which it was recognized, and revenue on systems that should have been reflected as deferred revenue on its balance sheet as of June 30, 2009. As a result of this news, so the lawsuit, the price of Hansen Medical Inc shares (NASDAQ: HNSN) declined $0.31 per share, more than 9%, to close on October 19, 2009, at $3.12 per share, on unusually heavy trading volume.
Hansen Medical Inc, located in Mountain View, California, develops, manufactures and sells generation of medical robotics designed for accurate positioning, manipulation and stable control of catheters and catheter-based technologies. Hansen Medical reported in 2007 Total Revenue of $10.09million and in 2008 Total Revenue of $30.23million. Shares of Hansen Medical Inc traded recently at $3.00 per share, down from its 52weekHigh of $11.89 per share, $14.71 per share in September ’08, $18.90 per share in July ’08, $28.91 per share in January ’08, and $37.50 per share in October 2007.